Berentx

Beren Therapeutics P.B.C. (traded as Berentx) is a fully integrated, clinical-stage biotechnology public benefit corporation headquartered in Thousand Oaks, California, with additional locations in South San Francisco, Boston, Budapest, Tokyo, and New Jersey. Founded in 2020 by Jason Camm, the company focuses on developing cyclodextrin-based therapeutics for conditions characterized by impaired intracellular cholesterol trafficking, including Niemann-Pick disease type C (NPC) and related neurodegenerative conditions. Beren's patient-aligned model integrates drug discovery, clinical development, manufacturing, and commercial expertise, working in close partnership with patient communities and caregivers. The company raised $300 million in 2026 financing and has approximately 103 employees.